WO2009095583A3 - Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale - Google Patents

Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale Download PDF

Info

Publication number
WO2009095583A3
WO2009095583A3 PCT/FR2009/050081 FR2009050081W WO2009095583A3 WO 2009095583 A3 WO2009095583 A3 WO 2009095583A3 FR 2009050081 W FR2009050081 W FR 2009050081W WO 2009095583 A3 WO2009095583 A3 WO 2009095583A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
epithelial origin
treating cancerous
aminopeptidase inhibitors
azaindole compounds
Prior art date
Application number
PCT/FR2009/050081
Other languages
English (en)
Other versions
WO2009095583A2 (fr
Inventor
Pierre Roux
Marion De Toledo
Jean-Paul Leonetti
Christelle Anguille
Original Assignee
Centre National De La Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scientifique filed Critical Centre National De La Recherche Scientifique
Priority to JP2010542670A priority Critical patent/JP2011509982A/ja
Priority to US12/812,501 priority patent/US20110046154A1/en
Priority to CA2712339A priority patent/CA2712339A1/fr
Priority to CN2009801053395A priority patent/CN101951905A/zh
Priority to EP09706702A priority patent/EP2234610A2/fr
Publication of WO2009095583A2 publication Critical patent/WO2009095583A2/fr
Publication of WO2009095583A3 publication Critical patent/WO2009095583A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Utilisation d'un composé choisi parmi un composé inhibiteur d'aminopeptidase et un composé aza-indole pour la fabrication d'un médicament destiné à la prévention ou au traitement des métastases cancéreuses chez l'homme ou l'animal.
PCT/FR2009/050081 2008-01-22 2009-01-21 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale WO2009095583A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2010542670A JP2011509982A (ja) 2008-01-22 2009-01-21 上皮起源からのガン転移を防ぎ又は処置する為のアミノペプチダーゼインヒビター又はアザインドール化合物の使用
US12/812,501 US20110046154A1 (en) 2008-01-22 2009-01-21 Use of aminopeptidase inhibitors or azaindole compounds for preventing or treating cancerous metastases from epithelial origin
CA2712339A CA2712339A1 (fr) 2008-01-22 2009-01-21 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale
CN2009801053395A CN101951905A (zh) 2008-01-22 2009-01-21 氨肽酶抑制剂或氮杂吲哚化合物用于预防或治疗上皮来源的癌转移的用途
EP09706702A EP2234610A2 (fr) 2008-01-22 2009-01-21 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0850389 2008-01-22
FR0850389A FR2926463B1 (fr) 2008-01-22 2008-01-22 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale

Publications (2)

Publication Number Publication Date
WO2009095583A2 WO2009095583A2 (fr) 2009-08-06
WO2009095583A3 true WO2009095583A3 (fr) 2010-03-11

Family

ID=39708890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/050081 WO2009095583A2 (fr) 2008-01-22 2009-01-21 Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale

Country Status (7)

Country Link
US (1) US20110046154A1 (fr)
EP (1) EP2234610A2 (fr)
JP (1) JP2011509982A (fr)
CN (1) CN101951905A (fr)
CA (1) CA2712339A1 (fr)
FR (1) FR2926463B1 (fr)
WO (1) WO2009095583A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
WO2012088420A1 (fr) * 2010-12-22 2012-06-28 The Trustees Of Columbia University In The City Of New York Modulateurs de l'histone acétyltransférase et leurs utilisations
CN102212511A (zh) * 2011-03-31 2011-10-12 山东大学 定点突变的嗜热菌f3因子重组蛋白及其应用
CN105541806A (zh) * 2015-12-25 2016-05-04 中国药科大学 巴比妥酸类化合物、制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039990A2 (fr) * 2000-11-14 2002-05-23 Novartis Ag Methode de criblage de composes antiproliferatifs et methode permettant d'inhiber une croissance tumorale
EP1382349A1 (fr) * 2001-04-27 2004-01-21 Nippon Kayaku Kabushiki Kaisha Immunotherapie supplementaire pouvant etre utilisee apres une ablation pulmonaire liee a un cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE602005005211T2 (de) * 2004-10-14 2009-03-19 F. Hoffmann-La Roche Ag Neue azaindol-thiazolinone als krebsmittel
US7855205B2 (en) * 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039990A2 (fr) * 2000-11-14 2002-05-23 Novartis Ag Methode de criblage de composes antiproliferatifs et methode permettant d'inhiber une croissance tumorale
EP1382349A1 (fr) * 2001-04-27 2004-01-21 Nippon Kayaku Kabushiki Kaisha Immunotherapie supplementaire pouvant etre utilisee apres une ablation pulmonaire liee a un cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COTE L ET AL: "Studies on nicotinamide derivatives.", JOURNAL OF BACTERIOLOGY APR 1951, vol. 61, no. 4, April 1951 (1951-04-01), pages 463 - 467, XP002560848, ISSN: 0021-9193 *
FUJII H ET AL: "Human Melanoma Invasion and Metastasis Enhancement by High Expression of Aminopeptidase N/CD13", CLINICAL & EXPERIMENTAL METASTASIS, XX, XX, vol. 13, no. 5, 1 January 1995 (1995-01-01), pages 337 - 344, XP002977602, ISSN: 0262-0898 *
KUSHNER S ET AL: "Experimental chemotherapy of tuberculosis; substituted nicotinamides.", THE JOURNAL OF ORGANIC CHEMISTRY NOV 1948, vol. 13, no. 6, November 1948 (1948-11-01), pages 834 - 836, XP002560847, ISSN: 0022-3263 *
SHEREMETEV, A.B. ET AL: "Synthesis of secondary and tertiary aminofurazans", RUSSIAN CHEMICAL BULLETIN, INTERNATIONAL EDITION, vol. 53, no. 3, 2004, pages 596 - 614, XP002550405 *
YONEDA J ET AL: "INHIBITION OF TUMOR INVASION AND EXTRACELLULAR MATRIX DEGRADATION BY UBENIMEX (BESTATIN)", CLINICAL & EXPERIMENTAL METASTASIS, XX, XX, vol. 10, no. 1, 1 January 1992 (1992-01-01), pages 49 - 59, XP009030476, ISSN: 0262-0898 *

Also Published As

Publication number Publication date
WO2009095583A2 (fr) 2009-08-06
JP2011509982A (ja) 2011-03-31
US20110046154A1 (en) 2011-02-24
EP2234610A2 (fr) 2010-10-06
CN101951905A (zh) 2011-01-19
FR2926463B1 (fr) 2010-08-13
CA2712339A1 (fr) 2009-08-06
FR2926463A1 (fr) 2009-07-24

Similar Documents

Publication Publication Date Title
AP2870A (en) Odcase inhibitors for the treatment of malaria
EP2063897A4 (fr) Inhibiteurs de kinases utiles pour le traitement de maladies prolifératives
EP2063896A4 (fr) Inhibiteurs de la kinase utiles dans le traitement de maladies prolifératives
HK1119696A1 (en) Pyridopyrimidinone inhibitors of pi3k pi3k
ZA200906946B (en) Inhibitors of iap
EP2026843A4 (fr) Utilisations thérapeutiques d'inhibiteurs de rtp801l
IL193484A0 (en) Gsk-3 inhibitors for the treatment of osteoporosis
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
ZA200805152B (en) Inhibitors of IAP
IL186339A0 (en) Dosage forms of risedronate
NL2000439A1 (nl) Therapeutische toepassingen van inhibitoren van RTP801.
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
EP2429292A4 (fr) Composés et compositions comprenant des inhibiteurs des cdk et méthodes de traitement du cancer
EA201170872A1 (ru) Ингибиторы протеинкиназы
SI2120932T1 (sl) Indazolni derivati kot kinazni inhibitorji za zdravljenje raka
TN2011000291A1 (en) Purine compounds
EP2318406A4 (fr) Composés inhibiteurs et procédés de traitement du cancer
BRPI0921278A2 (pt) Inibidores lisossomotrópicos de ceramidase ácida
WO2012065057A3 (fr) Inhibiteurs de la phosphatidylinositol 3-kinase et leurs procédés d'utilisation
EP1987838A4 (fr) Nouveau composé de traitement de tumeur
EA201270728A1 (ru) Пуриновые соединения
WO2009095583A3 (fr) Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale
HK1254607A1 (zh) 用於治療癌症的有機砷化合物
WO2010077310A3 (fr) Dérivés amides de l'acide éthacrynique
EP2015741A4 (fr) Inhibiteurs de l'histone desacétylase pour le traitement de la neurodégénération

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980105339.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09706702

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2712339

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010542670

Country of ref document: JP

Ref document number: 2009706702

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12812501

Country of ref document: US